FOLLICULAR LYMPHOMA

This large study tested whether combining two drugs (lenalidomide and rituximab) works better than standard chemotherapy plus rituximab for people with previously untreated follicular lymphoma, a type of blood cancer. Researchers enrolled over 1,000 patients to see which combinat…

This study tested a two-step, lower-intensity stem cell transplant for patients with high-risk blood cancers like leukemia and lymphoma. The goal was to control the cancer by first using low-dose chemotherapy and radiation to prepare the body, then infusing donor stem cells to at…

This study tested a new, more convenient schedule for radiation therapy given before CAR T-cell treatment. Ten adults with B-cell lymphoma that had returned or not responded to other treatments received radiation once a week for five weeks. The main goal was to see if this weekly…

This study tested whether adding the drug ibrutinib to standard rituximab treatment works better than rituximab alone for people newly diagnosed with follicular lymphoma. Researchers enrolled 445 older adults or those with other health conditions to compare how long patients stay…

This study tested a one-time treatment called tisagenlecleucel, a type of CAR-T cell therapy, in adults whose follicular lymphoma had returned or stopped responding to other treatments. Doctors collected and reprogrammed each patient's own immune cells to better find and attack t…

This study tested a new type of personalized cell therapy for children and young adults whose leukemia or lymphoma had come back or did not respond to standard treatments. Researchers collected a patient's own immune cells, genetically modified them in a lab to recognize a protei…

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This study tested whether a treatment called axicabtagene ciloleucel, a type of CAR-T cell therapy, could help people with slow-growing non-Hodgkin lymphoma that had come back or stopped responding to other treatments. It involved 159 participants whose cancer had progressed afte…

This first-in-human study tested a new oral drug called BR101801 in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early s…

This study aims to gather information on how well a cancer treatment called CAR T-cell therapy works for people living with HIV who also have certain blood cancers. Researchers will collect standard medical data from about 30 patients who have already received this therapy. The g…